CAMBRIDGE, MASSACHUSETTS – February 8, 2022 – Paragonix Technologies announced the first successful heart transplant at the University of Virginia Medical Center using it’s SherpaPak Cardiac Transport System (CTS). The SherpaPak technology provides a safe and effective way for hearts to be transported during the transplant process.
The University of Virginia Medical Center is one of the first in Virginia to utilize the Paragonix SherpaPak CTS system, marking their commitment to be a leader in transplant innovation. The Paragonix SherpaPak CTS replaces the consumer-grade cooler and ice system that has been used historically – a method that was long overdue for innovation. Bluetooth connection to the Paragonix app and web portal provides temperature tracking and real-time updates to the transplant team, providing these teams with information critical to this complicated surgery.
The SherpaPak is the leading FDA cleared and CE marked preservation device for heart transportation that provides a sterile, temperature and pressure-controlled environment for organs traveling between operating rooms. The Paragonix SherpaPak CTS protects donor hearts with its rigid, sterile container and maintains a temperature between 4-8ºC, a temperature range recommended by the International Society of Heart and Lung Transplantation as an optional donor heart preservation condition1.
For more information about Paragonix, visit www.paragonix.com.
About Paragonix Technologies
Paragonix Technologies markets organ transportation devices that safeguard organs during the journey between donor and recipient patients. Our devices incorporate clinically proven and medically trusted cold preservation techniques in a novel suspension system to provide unprecedented physical and thermal protection. Paragonix SherpaPak CTS is the only commercially available FDA cleared and CE marked transport device for heart transportation.
Follow us on Twitter: @ParagonixSherpa
Connect with us on LinkedIn: Paragonix Technologies
1. Copeland et al. Donor heart and lung procurement: A consensus statement. J Heart Lung Transplant. 2020
Adam Lafreniere, Director Marketing Operations